Marshall Edwards Inc. (Nasdaq: MSHL) 49.3% LOWER; reports results from failed phase III OVATURE trial of orally administered phenoxodiol in women with recurrent ovarian cancer determined that the trial did not show a statistically significant improvement in its primary (progression-free survival) or secondary (overall survival) endpoints. Click Here to read the full presser. ev3, Inc.